Trial · NCT04327661

Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness

NCT04327661, Phase 3, Completed, Vanda Pharmaceuticals; results first posted 2024-12-11

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness. Trials, record NCT04327661. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04327661

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
NCT number: NCT04327661
Status: Completed
Phases: Phase 3
Enrollment: 366 participants, actual
Lead sponsor: Vanda Pharmaceuticals
Conditions: Motion Sickness
Interventions: Tradipitant, Placebo
First posted: 2020-03-31
Last updated: 2024-12-11
Results first posted: 2024-12-11

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Prevention of Vomiting Measured by Vomiting Assessment (VA)	1 day	Prevention of vomiting measured by Vomiting Assessment (VA) score in tradipitant high dose. The VA is a 1-item questionnaire to objectively measure the incidence of emesis. Participants will indicate whether or not they have vomited. The Count of Participants indicates participants who vomited.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Prevention of Vomiting Measured by Vomiting Assessment (VA)	1 day		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group3

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Prevention of Vomiting Measured by Vomiting Assessment (VA)	Tradipitant High Dose	22	Participants
Prevention of Vomiting Measured by Vomiting Assessment (VA)	Tradipitant Low Dose	24	Participants
Prevention of Vomiting Measured by Vomiting Assessment (VA)	Placebo	54	Participants

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Tradipitant High Dose	121
Overall Study	STARTED	Tradipitant Low Dose	123
Overall Study	STARTED	Placebo	122
Overall Study	COMPLETED	Tradipitant High Dose	120
Overall Study	COMPLETED	Tradipitant Low Dose	123
Overall Study	COMPLETED	Placebo	122
Overall Study	NOT COMPLETED	Tradipitant High Dose	1
Overall Study	NOT COMPLETED	Tradipitant Low Dose	0
Overall Study	NOT COMPLETED	Placebo	0

Source ClinicalTrials.gov

Adverse events9

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Headache	Nervous system disorders	Tradipitant High Dose	10	120
other	Headache	Nervous system disorders	Tradipitant Low Dose	7	123
other	Headache	Nervous system disorders	Placebo	3	122
other	Somnolence	Nervous system disorders	Tradipitant High Dose	10	120
other	Somnolence	Nervous system disorders	Tradipitant Low Dose	8	123
other	Somnolence	Nervous system disorders	Placebo	1	122
other	Fatigue	General disorders	Tradipitant High Dose	10	120
other	Fatigue	General disorders	Tradipitant Low Dose	5	123
other	Fatigue	General disorders	Placebo	0	122

Source ClinicalTrials.gov

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Tradipitant High Dose	0	120
Total, all-cause mortality	Tradipitant Low Dose	0	123
Total, all-cause mortality	Placebo	0	122
Total, other adverse events	Tradipitant High Dose	26	120
Total, other adverse events	Tradipitant Low Dose	20	123
Total, other adverse events	Placebo	4	122
Total, serious adverse events	Tradipitant High Dose	0	120
Total, serious adverse events	Tradipitant Low Dose	0	123
Total, serious adverse events	Placebo	0	122

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
40103934	DERIVED	PubMed
42150111	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04327661

GET https://conductscience.org/api/trials/v1/NCT04327661/registered

API reference For AI assistants